CUMULATIVE
SUPPLEMENT 4
JAN'97-APR'97



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT
DIVISION OF DATABASE MANAGEMENT

Approved drug products with therapeutic equivalence

Prepared By
Division of Database Management
Office of Management
Center for Drug Evaluation and Research, FDA

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

Cumulative Supplement 4

APRIL 1997

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

CUMULATIVE SUPPLEMENT 4
APRIL 1997

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 17th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition. However, the overstruck data in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements (hard copy).

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 16th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 17th Edition.

1.2 COURT ORDER AFFECTING URUGUAY ROUND AGREEMENTS ACT-EXTENDED PATENTS

As a result of the April 4, 1996, decision of the United States Court of Appeals for the Federal Circuit in Merck, et al. v. Kessler, patent expiration dates for certain patents subject to patent term extensions under the Uruguay Round Agreements Act and to the patent term extension provisions at 35 U.S.C. § 156 may be changed. FDA has published a notice in the March 14, 1997, *Federal Register* advising NDA and NADA

applicants that patent expiration dates changed by the Merck decision must be submitted within 60 days. Because there may be changes in listed patents as a result of the Merck decision, users of this publication should consult the most recent supplement, and are encouraged to confirm that patent information upon which they intend to rely is current. (See the *Patent and Exclusivity Addendum* to the *Approved Drug Products with Therapeutic Equivalence Evaluations*, 16th Edition that explains the background information on this court decision).

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
CIBA GEIGY CORP (CIBA GEIGY)	NOVARTIS PHARMACEUTICAL CORP (NOVARTIS)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
CIBA GEIGY CORP PHARMACEUTICALS DIV (CIBA GEIGY)	NOVARTIS PHARMACEUTICAL CORP (NOVARTIS)
CIBA PHARMACEUTICAL CO DIV CIBA GEIGY CORP (CIBA)	NOVARTIS PHARMACEUTICAL CORP (NOVARTIS)
CIBA SELF MEDICATION INC DIV CIBA GEIGY CORP (CIBA)	NOVARTIS CONSUMER HEALTH INC (NOVARTIS)
CIBA VISION CORP (CIBA)	CIBA VISION CORPORATION A NOVARTIS COMPANY (CIBA)
CIBA VISION OPHTHALMICS DIV CIBA VISION CORP (CIBA)	CIBA VISION CORPORATION A NOVARTIS COMPANY (CIBA)
FERRING LABORATORIES INC (FERRING)	FERRING PHARMACEUTICALS INC (FERRING)
GEIGY PHARMACEUTICALS DIV CIBA GEIGY CORP (GEIGY)	NOVARTIS PHARMACEUTICAL CORP (NOVARTIS)
SANDOZ CONSUMER HEALTH CARE GROUP DIV SANDOZ PHARMACEUTICALS (SANDOZ)	NOVARTIS CONSUMER HEALTH INC (NOVARTIS)
SANDOZ PHARMACEUTICALS CORP DIV SANDOZ INC (SANDOZ)	NOVARTIS PHARMACEUTICAL CORP (NOVARTIS)
SANDOZ RESEARCH INSTITUTE INC (SANDOZ)	NOVARTIS PHARMACEUTCAL CORP (NOVARTIS)
SANOFI WINTHROP INC (SANOFI WINTHROP)	SANOFI PHARMACEUTICAL INC (SANOFI)
SURVIVAL TECHNOLOGY INC (SURVIVAL TECH)	MERIDIAN MEDICAL TECHNOLOGIES INC (MERIDIAN MEDCL TECHN)

1.4 ACYCLOVIR 200MG TABLET-REFERENCE LISTED DRUG

Novapharm's single source acyclovir tablets have been declared to be a reference listed drug for the 200 mg tablet in addition to the acylcovir (Zovirax) 800 mg tablet of the innovator. A generic firm wishing to submit an ANDA for a duplicate of the 200 mg acyclovir tablet will be eligible for a waiver of the *in vivo* determination of bioequivalence (1) if their product is proportionally similar in its active and inactive ingredients to their own 800 mg acyclovir tablet and (2) by doing an acceptable comparative dissolution test (dissolution profile) against Novopharm's 200 mg acyclovir reference listed drug.

Before a waiver of the *in vivo* determination of bioequivalence can be granted for the 200 mg acyclovir tablet, the generic firm must have completed an acceptable fasting and fed study comparing their acyclovir 800 mg tablet against the Zovirax 800 mg tablet.

For further information on the study designs, you should contact the Division of Bioequivalence, Office of Generic Drugs.

1.5 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

The following *Approved Drug Products with Therapeutic Equivalence Evaluations* files are now available on Internet and are updated each October and April: Prescription Drug Product List; OTC Drug Products; Discontinued Drug Products; and Appendices. The update in October will include drug products that have been approved through August and the update in April will include drug products that have been approved through December.

These files may be accessed on the Internet's World Wide Web. FDA's Internet site replaced the Agency's electronic bulletin board. To access the CDER Home Page, use this Uniform Resource Locator (URL): http://www.fda.gov/cder. You do not need an Internet connection to reach the FDA Home Page; you can use the free dial-up connection (800) 222-0185 for text based, non-graphical use only. For further assistance, please call (301) 443-4908.

The Prescription Drug Products and OTC Drug Product files will be available on a monthly basis in the near future.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1996) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1996*	MAR 1997	JUN 1997	SEP 1997
DRUG PRODUCTS LISTED	9392	9493		
SINGLE SOURCE	2383 (25.4%)	2387 (25.1%)		
MULTISOURCE	6905 (73.5%)	6991 (73.7%)		
THERAPEUTICALLY EQUIVALENT	6463 (68.8%)	6549 (69.0%)		
NOT THERAPEUTICALLY EQUIVALENT	442 (4.7%)	442 (4.7%)		
EXCEPTIONS[1]	104 (1.1%)	115 (1.2%)		
NEW MOLECULAR ENTITIES APPROVED	--	6		
NUMBER OF APPLICANTS	650	662		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

*Exceptions were originally included in the total count of the Multisource Drug Products. Beginning with December 1996, exceptions will no longer be included in the Multisource Drug Products total count, but will be included in the total count of the Drug Products Listed.

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE

> DLT >	AB	GRAHAM DM	325MG;50MG;40MG	N88743 001	
> DLT >				JUL 18, 1985	
> DLT >	AB		325MG;50MG;40MG	N88765 001	
> DLT >				MAR 27, 1985	
> DLT >	AB		325MG;50MG;40MG	N89067 001	
> DLT >				APR 19, 1985	
> ADD >		@	325MG;50MG;40MG	N88743 001	
> ADD >				JUL 18, 1985	
> ADD >		@	325MG;50MG;40MG	N88765 001	
> ADD >				MAR 27, 1985	
> ADD >		@	325MG;50MG;40MG	N89067 001	
> ADD >				APR 19, 1985	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	AA	EON	500MG;5MG	N40149 001	
				JAN 27, 1997	
	AA		750MG;7.5MG	N40149 002	
				JAN 27, 1997	
> ADD >	AA	VINTAGE PHARMS	500MG;2.5MG	N40144 002	
> ADD >				APR 25, 1997	
> ADD >	AA		650MG;7.5MG	N40155 001	
> ADD >				APR 14, 1997	
	AA	WATSON LABS	500MG;10MG	N40148 002	
				FEB 14, 1997	

LORTAB

	AA	+ GRAHAM DM	500MG;10MG	N40100 001	
				JAN 26, 1996	

NORCO

		+ WATSON LABS	325MG;10MG	N40148 001	
				FEB 14, 1997	

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

	AB	VINTAGE PHARMS	650MG;100MG	N74843 001	
				FEB 12, 1997	

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS; OTIC

TRIDESILON

	BAYER	2%;0.05%	N17914 001	
	@	2%;0.05%	N17914 001	

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

> ADD >	AB	AESGEN	200MG	N74833 001	
> ADD >				APR 22, 1997	
> ADD >	AB	ESI LEDERLE	200MG	N74872 001	
> ADD >				APR 22, 1997	
> ADD >	AB	LEK PHARM	200MG	N74750 001	
> ADD >				APR 22, 1997	
> ADD >	AB	LEMMON	200MG	N74828 001	
> ADD >				APR 22, 1997	
> ADD >	AB	MYLAN	200MG	N74727 001	
> ADD >				APR 22, 1997	
> ADD >	AB	NOVOPHARM	200MG	N74578 001	
> ADD >				APR 22, 1997	
> ADD >	AB	ROXANE	200MG	N74570 002	
> ADD >				APR 22, 1997	
> ADD >	AB	ZENITH GOLDLINE	200MG	N74674 001	
> ADD >				APR 22, 1997	

ZOVIRAX

> ADD >	AB	+ GLAXO WELLCOME	200MG	N18828 001	
> ADD >				JAN 25, 1985	

SUSPENSION; ORAL

ACYCLOVIR

> ADD >	AB	ALPHARMA	200MG/5ML	N74738 001	
> ADD >				APR 28, 1997	

ZOVIRAX

> ADD >	AB	+ GLAXO WELLCOME	200MG/5ML	N19909 001	
> ADD >				DEC 22, 1989	

TABLET; ORAL

ACYCLOVIR

> ADD >	AB	ESI LEDERLE	400MG	N74834 001	
> ADD >				APR 24, 1997	
> ADD >	AB		800MG	N74834 002	
> ADD >				APR 24, 1997	
> ADD >	AB	LEK PHARM	400MG	N74658 001	
> ADD >				APR 22, 1997	

ACYCLOVIR

TABLET; ORAL

> ADD >		**ACYCLOVIR**			
> ADD >	**AB**	LEK PHARM	**800MG**	**N74658 002**	
> ADD >				APR 22, 1997	
> ADD >	**AB**	NOVOPHARM	**400MG**	**N74556 002**	
> ADD >				APR 22, 1997	
> ADD >	**AB**		**800MG**	**N74556 003**	
> ADD >				APR 22, 1997	
> ADD >	+		200MG	N74556 001	
> ADD >				APR 22, 1997	
> ADD >	**AB**	ZENITH GOLDLINE	**400MG**	**N74836 001**	
> ADD >				APR 22, 1997	
> ADD >	**AB**		**800MG**	**N74836 002**	
> ADD >				APR 22, 1997	
		ZOVIRAX			
> ADD >	**AB**	GLAXO WELLCOME	**400MG**	**N20089 001**	
> ADD >				APR 30, 1991	
> ADD >	**AB** +		**800MG**	**N20089 002**	
> ADD >				APR 30, 1991	

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

> ADD >		**ACYCLOVIR SODIUM**			
> ADD >	**AP**	ABBOTT	**EQ 500MG BASE/VIAL**	**N74758 001**	
> ADD >				APR 22, 1997	
> ADD >	**AP**		**EQ 1GM BASE/VIAL**	**N74758 002**	
> ADD >				APR 22, 1997	
> ADD >	**AP**	BEDFORD	**EQ 500MG BASE/VIAL**	**N74596 002**	
> ADD >				APR 22, 1997	
> ADD >	**AP**		**EQ 1GM BASE/VIAL**	**N74596 001**	
> ADD >				APR 22, 1997	
> ADD >	+	FAULDING	EQ 25MG BASE/ML	N74720 001	
> ADD >				APR 22, 1997	
> ADD >	**AP**	SANOFI WINTHROP	**EQ 500MG BASE/VIAL**	**N74663 001**	
> ADD >				APR 22, 1997	
> ADD >	**AP**		**EQ 1GM BASE/VIAL**	**N74663 002**	
> ADD >				APR 22, 1997	
		ZOVIRAX			
> ADD >	**AP** +	GLAXO WELLCOME	**EQ 500MG BASE/VIAL**	**N18603 001**	
> ADD >				OCT 22, 1982	
> ADD >	**AP** +		**EQ 1GM BASE/VIAL**	**N18603 002**	
> ADD >				JUN 29, 1989	

ALENDRONATE SODIUM

TABLET; ORAL

	FOSAMAX			
> ADD >	MERCK	EQ 5MG BASE		N20560 003
> ADD >				APR 25, 1997

ALPRAZOLAM

TABLET; ORAL

	ALPRAZOLAM		
AB	ROYCE LABS	**0.25MG**	**N74479 001**
			JAN 21, 1997
AB		**0.5MG**	**N74479 002**
			JAN 21, 1997
AB		**1MG**	**N74479 003**
			JAN 21, 1997

AMIKACIN SULFATE

INJECTABLE; INJECTION

	AMIKACIN SULFATE		
AP	ELKINS SINN	**EQ 50MG BASE/ML**	**N63274 001**
			MAY 18, 1992
	@	EQ 50MG BASE/ML	N63274 001
			MAY 18, 1992
> ADD >	AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
> ADD >	ABBOTT	EQ 500MG BASE/100ML	N64146 001
> ADD >			APR 02, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER		
ABBOTT	5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19683 004
		NOV 07, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
@ ABBOTT 5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML N19683 004 NOV 07, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 2.75%;33MG/100ML;10GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML N20678 002 MAR 26, 1997

CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 2.75%;33MG/100ML;25GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML N20678 005 MAR 26, 1997

CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 2.75%;33MG/100ML;5GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML N20678 001 MAR 26, 1997

CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%;33MG/100ML;10GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 009 MAR 26, 1997

CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%;33MG/100ML;20GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 011 MAR 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%;33MG/100ML;25GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 012 MAR 26, 1997

CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%;33MG/100ML;5GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 008 MAR 26, 1997

CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;10GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 016 MAR 26, 1997

CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;15GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 017 MAR 26, 1997

CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;20GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 018 MAR 26, 1997

CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;25GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 019 MAR 26, 1997

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;35GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 021 MAR 26, 1997

AMINOPHYLLINE

INJECTABLE; INJECTION

> DLT >		**AMINOPHYLLIN**			
> DLT >	**AP**	+ SEARLE	**25MG/ML**	**N87243 001**	
> DLT >				MAY 24, 1982	
> ADD >		@	25MG/ML	N87243 001	
> ADD >				MAY 24, 1982	
		AMINOPHYLLINE			
> DLT >	**AP**	ELKINS SINN	**25MG/ML**	**N87239 001**	
> ADD >	**AP**	+	**25MG/ML**	**N87239 001**	

TABLET, EXTENDED RELEASE; ORAL

> DLT >		PHYLLOCONTIN		
> DLT >		+ PURDUE FREDERICK	225MG	N86760 001
> ADD >		@	225MG	N86760 001

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

		LIMBITROL		
AB	+	ROCHE	**EQ 25MG BASE;10MG**	**N16949 002**
		LIMBITROL DS		
AB	+	ROCHE	**EQ 25MG BASE;10MG**	**N16949 002**

AMOXICILLIN

CAPSULE; ORAL

		AMOXIL		
AB	+	SMITHKLINE BEECHAM	**250MG**	**N50459 001**
AB			**250MG**	**N62216 001**
AB	+		250MG	N62216 001
AB	+		**500MG**	**N50459 002**
AB			**500MG**	**N62216 004**
AB	+		**500MG**	**N62216 004**
		@	250MG	N50459 001
		@	500MG	N50459 002

POWDER FOR RECONSTITUTION; ORAL

		AMOXIL		
AB	+	SMITHKLINE BEECHAM	**125MG/5ML**	**N50460 001**
AB			**125MG/5ML**	**N62226 001**
AB	+		125MG/5ML	N62226 001
AB	+		**250MG/5ML**	**N50460 002**
AB	+		**50MG/ML**	**N50460 005**
AB			**250MG/5ML**	**N62226 002**
AB	+		250MG/5ML	N62226 002

AMOXICILLIN

POWDER FOR RECONSTITUTION; ORAL

		AMOXIL		
AB		SMITHKLINE BEECHAM	**50MG/ML**	**N62226 005**
AB	+		**50MG/ML**	**N62226 005**
	@		125MG/5ML	N50460 001
	@		250MG/5ML	N50460 002
	@		50MG/ML	N50460 005
	LAROTID			
AB		SMITHKLINE BEECHAM	**50MG/ML**	**N50460 006**
	@		50MG/ML	N50460 006

AMPHOTERICIN B

OINTMENT; TOPICAL

		FUNGIZONE		
	+	APOTHECON	3%	N50313 001
	@		3%	N50313 001

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

		AGRYLIN		
		ROBERTS LABS	EQ 0.5MG BASE	N20333 001
				MAR 14, 1997
	+		EQ 1MG BASE	N20333 002
				MAR 14, 1997

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

		ATRACURIUM BESYLATE		
AP		ABBOTT	**10MG/ML**	**N74633 001**
				DEC 23, 1996
AP		FAULDING	**10MG/ML**	**N74740 001**
				MAR 28, 1997
AP		OHMEDA	**10MG/ML**	**N74753 001**
				JAN 23, 1997
		ATRACURIUM BESYLATE PRESERVATIVE FREE		
AP		ABBOTT	**10MG/ML**	**N74633 001**
				DEC 23, 1996
AP			**10MG/ML**	**N74639 001**
				MAR 25, 1997
AP		FAULDING	**10MG/ML**	**N74741 001**
				MAR 28, 1997

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP		OHMEDA	10MG/ML	N74768 001 JAN 23, 1997

TRACRIUM

AP	+	GLAXO WELLCOME	10MG/ML	N18831 001 NOV 23, 1983
AP	+		10MG/ML	N18831 002 JUN 20, 1985

TRACRIUM PRESERVATIVE FREE

AP	+	GLAXO WELLCOME	10MG/ML	N18831 001 NOV 23, 1983

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HCL AND ATROPINE SULFATE

> DLT >	AA	ROXANE	0.025MG;2.5MG	N86057 001
> ADD >		@	0.025MG;2.5MG	N86057 001

DIPHENOXYLATE HCL W/ ATROPINE SULFATE

> DLT >	AA	KV PHARM	0.025MG;2.5MG	N85659 001
> ADD >		@	0.025MG;2.5MG	N85659 001

AZITHROMYCIN DIHYDRATE

INJECTABLE; INJECTION

ZITHROMAX

	+	PFIZER	EQ 500MG BASE/VIAL	N50733 001 JAN 30, 1997

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL

CORTISPORIN

> DLT >	+	GLAXO WELLCOME	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM	N50168 002 MAY 04, 1984
> DLT >				
> DLT >				
> ADD >	+	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM	N50168 002 MAY 04, 1984
> ADD >				
> ADD >				

> ADD >

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

> ADD >

SUSPENSION/DROPS; OPHTHALMIC

> ADD > BETOPTIC PILO

> ADD >	+	ALCON	EQ 0.25% BASE;1.75%	N20619 001 APR 17, 1997
> ADD >				

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

> DLT >	AP	+ BAXTER HLTHCARE	200MG/100ML	N19837 002 APR 12, 1989
> DLT >				
> DLT >	AP	+	400MG/100ML	N19837 001 APR 12, 1989
> DLT >				
> ADD >		@	200MG/100ML	N19837 002 APR 12, 1989
> ADD >				
> ADD >		@	400MG/100ML	N19837 001 APR 12, 1989
> ADD >				

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN

	+	ALLERGAN	0.5%	N20490 001 MAR 13, 1997

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT ONE

	+	SYNTEX	2%	N19881 001 FEB 07, 1997

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP		ABBOTT	1MG/ML	N74620 001 JAN 22, 1997
AP			1MG/ML	N74626 001 JAN 23, 1997
AP			2MG/ML	N74620 002 JAN 22, 1997

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

	BUTORPHANOL TARTRATE PRESERVATIVE FREE			
AP	ABBOTT	2MG/ML	N74626 002	JAN 23, 1997
	STADOL			
AP	+ APOTHECON	2MG/ML	N17857 004	
	STADOL PRESERVATIVE FREE			
AP	+ APOTHECON	1MG/ML	N17857 001	
AP	+	2MG/ML	N17857 002	

CALCIPOTRIENE

SOLUTION; TOPICAL

	DOVONEX		
	+ BRISTOL MYERS SQUIBB	0.005%	N20611 001 MAR 03, 1997

CAPTOPRIL

TABLET; ORAL

	CAPOTEN			
AB	+ BRISTOL MYERS SQUIBB	25MG	N18343 002	
AB		25MG	N18343 002	
	CAPTOPRIL			
AB	PUREPAC PHARM	12.5MG	N74640 001	MAR 31, 1997
AB		25MG	N74640 002	MAR 31, 1997
AB		50MG	N74640 003	MAR 31, 1997
AB		100MG	N74640 004	MAR 31, 1997
AB	WOCKHARDT	12.5MG	N74532 001	MAR 28, 1997
AB		25MG	N74532 002	MAR 28, 1997
AB		50MG	N74532 003	MAR 28, 1997
AB		100MG	N74532 004	MAR 28, 1997

CARBAMAZEPINE

TABLET; ORAL

	EPITOL			
AB	LEMMON	200MG	N70541 001	SEP 17, 1986
AB	TEVA	200MG	N70541 001	SEP 17, 1986

TABLET, CHEWABLE; ORAL

	EPITOL			
AB	LEMMON	100MG	N73524 001	JUL 29, 1992
AB	TEVA	100MG	N73524 001	JUL 29, 1992

CARBIDOPA; LEVODOPA

TABLET; ORAL

	CARBIDOPA AND LEVODOPA			
AB	LEMMON	10MG;100MG	N73618 001	AUG 28, 1992
AB		25MG;100MG	N73589 001	AUG 28, 1992
AB		25MG;250MG	N73607 001	AUG 28, 1992
AB	TEVA	10MG;100MG	N73618 001	AUG 28, 1992
AB		25MG;100MG	N73589 001	AUG 28, 1992
AB		25MG;250MG	N73607 001	AUG 28, 1992

CARISOPRODOL

TABLET; ORAL

	CARISOPRODOL			
AA	AMIDE PHARM	350MG	N40188 001	MAR 07, 1997

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	CEFAZOLIN SODIUM			
AP	LEMMON	EQ 250MG BASE/VIAL	N63016 001	MAR 14, 1989

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	LEMMON	EQ 500MG BASE/VIAL	N63016 002 MAR 14, 1989		
AP		EQ 1GM BASE/VIAL	N63016 003 MAR 14, 1989		
AP		EQ 5GM BASE/VIAL	N63018 001 MAR 05, 1990		
AP		EQ 10GM BASE/VIAL	N63018 002 MAR 05, 1990		
AP	TEVA	EQ 250MG BASE/VIAL	N63016 001 MAR 14, 1989		
AP		EQ 500MG BASE/VIAL	N63016 002 MAR 14, 1989	> DLT > > ADD >	
AP		EQ 1GM BASE/VIAL	N63016 003 MAR 14, 1989	> ADD > > DLT >	
AP		EQ 5GM BASE/VIAL	N63018 001 MAR 05, 1990	> ADD > > ADD >	
AP		EQ 10GM BASE/VIAL	N63018 002 MAR 05, 1990	> ADD > > ADD >	

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
OPHTHOCORT

+	PARKE DAVIS	10MG/GM;5MG/GM; 10,000 UNITS/GM	N50201 002
@		10MG/GM;5MG/GM; 10,000 UNITS/GM	N50201 002

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL
CHLOROMYCETIN PALMITATE

> DLT > > ADD >	PARKE DAVIS @	EQ 150MG BASE/5ML EQ 150MG BASE/5ML	N62301 001 N62301 001

CHLORDIAZEPOXIDE

TABLET; ORAL
LIBRITABS

> DLT > > ADD >	ROCHE @	10MG 10MG	N85481 001 N85481 001

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
CHLORHEXIDINE GLUCONATE

AT	LEMMON	0.12%	N74522 001 DEC 15, 1995
AT	TEVA	0.12%	N74522 001 DEC 15, 1995

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
NESACAINE-MPF

AP	+ ASTRA	2%	N09435 003	
AP	+	2%	N09435 006 MAY 02, 1996	
AP	+	3%	N09435 004	
AP	+	3%	N09435 007 MAY 02, 1996	
	@	2%	N09435 003	
	@	3%	N09435 004	

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
CHLORPHENIRAMINE MALEATE

AA	KV PHARM	4MG	N87164 001
@		4MG	N87164 001

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE

@	LEMMON	50MG	N88651 001 MAY 30, 1985
@	TEVA	50MG	N88651 001 MAY 30, 1985

THALITONE

BX	HORUS THERAP	25MG	N88051 001 NOV 12, 1982
+		15MG	N19574 001 DEC 20, 1988
BX	MONARCH PHARMS	25MG	N19574 002 FEB 12, 1992
+		15MG	N19574 001 DEC 20, 1988

CHLORTHALIDONE

TABLET; ORAL
THALITONE

	@ MONARCH PHARMS	25MG	N88051 001 NOV 12, 1982	

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE

AA	LEMMON	**500MG**	**N89859 001** MAY 04, 1988	
AA	TEVA	**500MG**	**N89859 001** MAY 04, 1988	

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	LEMMON	**200MG**	**N74365 001** FEB 28, 1995	
AB		**300MG**	**N74365 002** FEB 28, 1995	
AB		**400MG**	**N74365 003** FEB 28, 1995	
AB		**800MG**	**N74365 004** FEB 28, 1995	
AB	SIDMAK LABS NJ	**200MG**	**N74568 001** FEB 27, 1997	
AB		**300MG**	**N74568 002** FEB 27, 1997	
AB		**400MG**	**N74568 003** FEB 27, 1997	
AB		**800MG**	**N74566 001** FEB 27, 1997	
AB	TEVA	**200MG**	**N74365 001** FEB 28, 1995	
AB		**300MG**	**N74365 002** FEB 28, 1995	> DLT > > DLT >
AB		**400MG**	**N74365 003** FEB 28, 1995	> ADD > > ADD >
AB		**800MG**	**N74365 004** FEB 28, 1995	

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CIMETIDINE HCL

AP	SANOFI	**EQ 300MG BASE/2ML**	**N74296 001** MAR 28, 1997
AP		**EQ 300MG BASE/2ML**	**N74412 001** MAR 28, 1997

SOLUTION; ORAL
CIMETIDINE HCL

AA	PHARM ASSOC	**EQ 300MG BASE/5ML**	**N74553 001** JAN 27, 1997

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE

AA	LEMMON	**EQ 0.5MG BASE/5ML**	**N73399 001** JUN 30, 1994
AA	TEVA	**EQ 0.5MG BASE/5ML**	**N73399 001** JUN 30, 1994

TABLET; ORAL
CLEMASTINE FUMARATE

AB	LEMMON	**2.68MG**	**N73283 001** JAN 31, 1992
	@	1.34MG	N73282 001 JAN 31, 1992
AB	TEVA	**2.68MG**	**N73283 001** JAN 31, 1992
	@	1.34MG	N73282 001 JAN 31, 1992

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

AP	QUAD PHARMS	**EQ 150MG BASE/ML**	**N62795 001** DEC 21, 1987
	@	EQ 150MG BASE/ML	N62795 001 DEC 21, 1987

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

AT	LEMMON	**EQ 1% BASE**	**N62930 001** JUN 28, 1989

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

AT	TEVA	EQ 1% BASE	N62930 001	JUN 28, 1989

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
CLOMIPRAMINE HCL

> ADD >	AB	NOVOPHARM	25MG	N74849 001 APR 04, 1997
> ADD >				
> ADD >	AB		50MG	N74849 002 APR 04, 1997
> ADD >				
> ADD >	AB		75MG	N74849 003 APR 04, 1997
> ADD >				

CLONAZEPAM

TABLET; ORAL
KLONOPIN

> ADD >	+	ROCHE	0.125MG	N17533 005 APR 09, 1997
> ADD >				
> ADD >			0.25MG	N17533 006 APR 09, 1997
> ADD >				

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION
INTAL

	+	FISONS	0.8MG/INH	N18887 001 DEC 05, 1985
	+	RHONE POULENC RORER	0.8MG/INH	N18887 001 DEC 05, 1985

CAPSULE; INHALATION
INTAL

	+	FISONS	20MG	N16990 001
	+	RHONE POULENC RORER	20MG	N16990 001

SOLUTION; INHALATION
INTAL

AN	+	FISONS	10MG/ML	N18596 001 MAY 28, 1982

CROMOLYN SODIUM

SOLUTION; INHALATION
INTAL

AN	+	RHONE POULENC RORER	10MG/ML	N18596 001 MAY 28, 1982

SOLUTION/DROPS; OPHTHALMIC
OPTICROM

	@	FISONS	4%	N18155 001 OCT 03, 1984
	@	RHONE POULENC RORER	4%	N18155 001 OCT 03, 1984

SPRAY, METERED; NASAL
NASALCROM

	+	FISONS	5.2MG/SPRAY	N18306 001 MAR 18, 1983

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
AK-PENTOLATE

AT		AKORN	1%	N85555 001
	@		1%	N85555 001

AKPENTOLATE

AT		AKORN	1%	N40164 001 JAN 13, 1997
AT			2%	N40165 001 JAN 13, 1997

CYCLOGYL

AT	+	ALCON	2%	N84108 001

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION
CYCLOPHOSPHAMIDE

> ADD >	AP	ASTA	100MG/VIAL	N88371 001 JUL 03, 1986
> ADD >				
> ADD >	AP		200MG/VIAL	N88372 001 JUL 03, 1986
> ADD >				
> ADD >	AP		500MG/VIAL	N88373 001 JUL 03, 1986
> ADD >				
> ADD >	AP		1GM/VIAL	N88374 001 SEP 24, 1986
> ADD >				
> DLT >	AP	ELKINS SINN	100MG/VIAL	N88371 001 JUL 03, 1986
> DLT >				

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

> DLT >	**AP**	ELKINS SINN	**200MG/VIAL**	**N88372 001**	
> DLT				JUL 03, 1986	
> DLT >	**AP**		**500MG/VIAL**	**N88373 001**	
> DLT >				JUL 03, 1986	
> DLT >	**AP**		**1GM/VIAL**	**N88374 001**	
> DLT >				SEP 24, 1986	

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE

> DLT >	**AP**	RHONE POULENC RORER	**EQ 20MG BASE/VIAL**	**N61876 001**	
> ADD >		@	EQ 20MG BASE/VIAL	N61876 001	
> DLT >	**AP**	+ WYETH AYERST	**EQ 20MG BASE/VIAL**	**N50484 001**	
> ADD >		@	EQ 20MG BASE/VIAL	N50484 001	

DAUNORUBICIN HCL

> DLT >	**AP**	BEDFORD	**EQ 20MG BASE/VIAL**	**N64103 001**	
> DLT >				FEB 03, 1995	
> ADD >		+	EQ 20MG BASE/VIAL	N64103 001	
> ADD >				FEB 03, 1995	

> ADD > DELAVIRDINE MESYLATE

> ADD > TABLET; ORAL

> ADD > RESCRIPTOR

> ADD >	+	PHARMACIA AND UPJOHN	100MG	N20705 001
> ADD >				APR 04, 1997

DEXAMETHASONE SODIUM PHOSPHATE

CREAM; TOPICAL

DECADRON

	+	MERCK SHARP DOHME	EQ 0.1% PHOSPHATE	N11983 002
	@		EQ 0.1% PHOSPHATE	N11983 002

DEXTROTHYROXINE SODIUM

TABLET; ORAL

CHOLOXIN

		KNOLL PHARM	1MG	N12302 005
	@		1MG	N12302 005

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HCL

AB		WEST WARD	**10MG**	**N40204 001**
				FEB 28, 1997

DIETHYLSTILBESTROL

> DLT > TABLET; ORAL

> DLT > DIETHYLSTILBESTROL

> DLT >		LILLY	1MG	N04041 004
> DLT >		+	5MG	N04041 005
> ADD >		@	1MG	N04041 004
> ADD >		@	5MG	N04041 005

> DLT > STILBESTROL

> DLT >		TABLICAPS	0.5MG	N83004 001
> ADD >		@	0.5MG	N83004 001

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

AP		ELKINS SINN	**50MG/ML**	**N84767 001**
		@	50MG/ML	N84767 001

DOXAZOSIN MESYLATE

TABLET; ORAL

CARDURA

		PFIZER	EQ 1MG BASE	N19668 001
				NOV 02, 1990
		+	EQ 8MG BASE	N19668 004
				NOV 02, 1990
		+	EQ 1MG BASE	N19668 001
				NOV 02, 1990
			EQ 8MG BASE	N19668 004
				NOV 02, 1990

ECONAZOLE NITRATE

CREAM; TOPICAL

SPECTAZOLE

		+ J AND J	1%	N18751 001
				DEC 23, 1982

ECONAZOLE NITRATE

CREAM; TOPICAL
SPECTAZOLE
+ JOHNSON RW 1% N18751 001 DEC 23, 1982

ERYTHROMYCIN

SOLUTION; TOPICAL
ERYTHROMYCIN
AT STIEFEL **2%** **N64127 001** FEB 14, 1997

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21
ALESSE
+ WYETH AYERST 0.02MG;0.1MG N20683 001 MAR 27, 1997

TABLET; ORAL-28
ALESSE
WYETH AYERST 0.02MG;0.1MG N20683 002 MAR 27, 1997

ETODOLAC

TABLET; ORAL
ETODOLAC
> ADD > **AB** EON **400MG** **N74903 001** APR 11, 1997
> ADD >
AB INVAMED **400MG** **N74846 001** FEB 28, 1997
AB PUREPAC PHARM **400MG** **N74819 001** FEB 28, 1997
> ADD > **AB** ROYCE LABS **400MG** **N74892 001** APR 16, 1997
> ADD >
AB ZENITH GOLDLINE **400MG** **N74883 001** FEB 28, 1997

LODINE
AB WYETH AYERST **400MG** **N18922 004** JUL 29, 1993

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE
> DLT > **AP** IMMUNEX **20MG/ML** **N74513 001** MAR 14, 1996
> DLT >
> ADD > **AP** SUPERGEN **20MG/ML** **N74513 001** MAR 14, 1996
> ADD >

FLUCONAZOLE

INJECTABLE; INJECTION
DIFLUCAN
+ PFIZER 200MG/100ML N19950 001 JAN 29, 1990

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
+ PFIZER 200MG/100ML N19950 003 SEP 29, 1992
@ 2MG/ML N19950 005 JUL 08, 1994

DIFLUCAN IN SODIUM CHLORIDE 0.9%
+ PFIZER 200MG/100ML N19950 001 JAN 29, 1990

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
+ PFIZER 200MG/100ML N19950 002 JAN 29, 1990
@ 2MG/ML N19950 004 JUL 08, 1994

FLURBIPROFEN

TABLET; ORAL
FLURBIPROFEN
> ADD > **AB** SIDMAK LABS NJ **50MG** **N74647 001** APR 01, 1997
> ADD >
> ADD > **AB** **100MG** **N74647 002** APR 01, 1997
> ADD >

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE
> ADD > **AB** SIDMAK LABS NJ **5MG** **N74619 001** APR 04, 1997
> ADD >
> ADD > **AB** **10MG** **N74619 002** APR 04, 1997
> ADD >

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL
GRIFULVIN V

> ADD >		J AND J	125MG/5ML	N62483 001 JAN 26, 1984
> DLT >		JOHNSON RW	125MG/5ML	N62483 001 JAN 26, 1984

GUANFACINE HYDROCHLORIDE

TABLET; ORAL
GUANFACINE HCL

AB	AMIDE PHARM	EQ 1MG BASE	N74673 001 FEB 28, 1997
AB		EQ 2MG BASE	N74673 002 FEB 28, 1997
AB	MYLAN	EQ 1MG BASE	N74796 001 JAN 27, 1997
AB		EQ 2MG BASE	N74796 002 JAN 27, 1997

HEPARIN SODIUM

INJECTABLE; INJECTION
HEP FLUSH KIT IN PLASTIC CONTAINER

AP	FUJISAWA	10 UNITS/ML	N17029 017 DEC 05, 1985
AP		100 UNITS/ML	N17029 018 DEC 05, 1985
	@	10 UNITS/ML	N17029 017 DEC 05, 1985
	@	100 UNITS/ML	N17029 018 DEC 05, 1985

HEPARIN SODIUM

AP	FUJISAWA	20,000 UNITS/ML	N17029 004
AP	STERIS	1,000 UNITS/ML	N17064 002
	@	1,000 UNITS/ML	N17064 002

HYDROCORTISONE

CREAM; TOPICAL
DERMACORT

> ADD >	AT	MONARCH PHARMS	1%	N83011 002
> DLT >	AT	SOLVAY	1%	N83011 002

PROCTOCORT

> ADD >	AT	MONARCH PHARMS	1%	N83011 001
> DLT >	AT	SOLVAY	1%	N83011 001

HYDROCORTISONE; UREA

CREAM; TOPICAL
ALPHADERM

> ADD >	@ BIOGLAN	1%;10%	N86008 001
> DLT >	@ VIVAN	1%;10%	N86008 001

HYDROCORTISONE BUTEPRATE

CREAM; TOPICAL
PANDEL

+	SAVAGE LABS	0.1%	N20453 001 FEB 28, 1997

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION
HYDROCORTISONE SODIUM SUCCINATE

AP	ELKINS SINN	EQ 1GM BASE/VIAL	N87569 001
	@	EQ 1GM BASE/VIAL	N87569 001

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL
HYDROXYZINE HCL

AB	KV PHARM	10MG	N87819 001 JUN 23, 1982
AB		25MG	N87820 001 JUN 23, 1982
AB		50MG	N87821 001 JUN 23, 1982
AB		100MG	N87822 001 JUN 23, 1982
	@	10MG	N87819 001 JUN 23, 1982
	@	25MG	N87820 001 JUN 23, 1982
	@	50MG	N87821 001 JUN 23, 1982

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

	HYDROXYZINE HCL				
	@ KV PHARM	100MG	N87822 001 JUN 23, 1982	> ADD >	

HYDROXYZINE PAMOATE

CAPSULE; ORAL

	HY-PAM				
AB	EON	**EQ 25MG HCL**	**N87479 001**	> ADD >	
	HYDROXYZINE PAMOATE				
AB	EON	**EQ 25MG HCL**	**N87479 001**	> ADD >	

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

	IDAMYCIN PFS				
	+ PHARMACIA AND UPJOHN	1MG/ML	N50734 001 FEB 17, 1997	> ADD >	

IMIQUIMOD

CREAM; TOPICAL

	ALDARA				
	+ 3M	5%	N20723 001 FEB 27, 1997	> ADD >	

INDAPAMIDE

TABLET; ORAL

	INDAPAMIDE				
AB	MYLAN	**1.25MG**	**N74461 002** MAR 26, 1997		
AB	NOVOPHARM	**1.25MG**	**N74665 001** APR 04, 1997	> DLT >	
AB		**2.5MG**	**N74665 002** APR 04, 1997	> ADD >	

IOPAMIDOL

INJECTABLE; INJECTION

	IOPAMIDOL-250				
AP	FUJISAWA	51%	**N74679 001** APR 02, 1997	> ADD >	
	IOPAMIDOL-300				
AP	ABBOTT	61%	**N74638 001** APR 30, 1997	> ADD >	
AP	FUJISAWA	61%	**N74679 002** APR 02, 1997	> ADD >	
	IOPAMIDOL-300 IN PLASTIC CONTAINER				
AP	ABBOTT	61%	**N74637 001** APR 03, 1997	> ADD >	
	IOPAMIDOL-370				
AP	FUJISAWA	76%	**N74679 003** APR 02, 1997	> ADD >	
	ISOVUE-250				
AP	+ BRACCO	51%	**N18735 007** JUL 06, 1992	> ADD >	
AP	+	51%	**N20327 002** OCT 12, 1994	> ADD >	

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

	ATROVENT				
AN	+ BOEHRINGER INGELHEIM	0.02%	**N20228 001** SEP 29, 1993		
	IPRATROPIUM BROMIDE				
AN	DEY	0.02%	**N74755 001** JAN 10, 1997		

ISONIAZID

SYRUP; ORAL

	ISONIAZID				
AA	CAROLINA MEDCL	**50MG/5ML**	**N88235 001** NOV 10, 1983	> DLT >	
	+	50MG/5ML	N88235 001 NOV 10, 1983	> ADD >	
	LANIAZID				
AA	LANNETT	**50MG/5ML**	**N89243 001** FEB 03, 1986	> DLT >	
	@	50MG/5ML	N89243 001 FEB 03, 1986	> ADD >	

ITRACONAZOLE

SOLUTION; ORAL
SPORANOX
+ JANSSEN — 10MG/ML — N20657 001 — FEB 21, 1997

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM
> ADD > **AP** PHARMACHEMIE — **EQ 50MG BASE/VIAL** — **N89628 001** — APR 17, 1997
> ADD >
> ADD > **AP** — **EQ 100MG BASE/VIAL** — **N89915 001** — APR 17, 1997
> ADD >

TABLET; ORAL
LEUCOVORIN CALCIUM
AB PHARMACHEMIE — **EQ 5MG BASE** — **N73099 001** — MAR 28, 1997
AB — **EQ 25MG BASE** — **N73101 001** — MAR 28, 1997

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LUPRON DEPOT-3
+ TAP HOLDINGS — 11.25MG/VIAL — N20708 001 — MAR 07, 1997

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL
LITHOBID
SOLVAY — 300MG — N18027 001
+ — 300MG — N18027 001

LORAZEPAM

SOLUTION; ORAL
LORAZEPAM
+ ROXANE — 0.5MG/5ML — N74648 001 — MAR 18, 1997

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
MECLIZINE HCL
> DLT > **AA** KV PHARM — **12.5MG** — **N85524 001**
> DLT > **AA** — **25MG** — **N85523 001**
> ADD > @ — 12.5MG — N85524 001
> ADD > @ — 25MG — N85523 001
AA VINTAGE PHARMS — **12.5MG** — **N40179 001** — JAN 30, 1997
AA — **25MG** — **N40179 002** — JAN 30, 1997

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION
HUMEGON
AB + ORGANON — **75 IU/VIAL;75 IU/VIAL** — **N20328 001** — SEP 01, 1994
AB — **75 IU/VIAL;75 IU/VIAL** — **N20328 001** — SEP 01, 1994
AB + — **150 IU/VIAL;150 IU/VIAL** — **N20328 002** — SEP 01, 1994
AB — **150 IU/VIAL;150 IU/VIAL** — **N20328 002** — SEP 01, 1994

REPRONAL
AB FERRING — **75 IU/VIAL;75 IU/VIAL** — **N73598 001** — JAN 30, 1997
AB — **150 IU/VIAL;150 IU/VIAL** — **N73599 001** — JAN 30, 1997

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL
MEPERIDINE HCL
AA ROXANE — **50MG** — **N40110 001** — MAR 12, 1997
AA — **100MG** — **N40110 002** — MAR 12, 1997

METAPROTERENOL SULFATE

SYRUP; ORAL
METAPROTERENOL SULFATE
AA JVL — **10MG/5ML** — **N74702 001** — MAR 24, 1997

METAPROTERENOL SULFATE

SYRUP; ORAL

		METAPROTERENOL SULFATE		
> DLT >	**AA**	MORTON GROVE	**10MG/5ML**	**N71656 001** OCT 13, 1987
> DLT				
> ADD >		@	10MG/5ML	N71656 001 OCT 13, 1987
> ADD >				

METFORMIN HYDROCHLORIDE

TABLET; ORAL

		GLUCOPHAGE		
> DLT >		BRISTOL MYERS SQUIBB	500MG	N20357 001 DEC 29, 1994
> DLT >				
> DLT >		+	850MG	N20357 002 DEC 29, 1994
> DLT >				
> ADD >			500MG	N20357 001 MAR 03, 1995
> ADD >				
> ADD >		+	850MG	N20357 002 MAR 03, 1995
> ADD >				

METHACHOLINE CHLORIDE

POWDER FOR RECONSTITUTION; INHALATION

	PROVOCHOLINE		
	METHAPHARM	100MG/VIAL	N19193 001 OCT 31, 1986
	ROCHE	100MG/VIAL	N19193 001 OCT 31, 1986

METHOTREXATE SODIUM

INJECTABLE; INJECTION

		MEXATE-AQ PRESERVED		
AP		BRISTOL MYERS	**EQ 25MG BASE/ML**	**N89887 001** APR 14, 1989
		@ BRISTOL MYERS SQUIBB	EQ 25MG BASE/ML	N89887 001 APR 14, 1989

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

		METOCLOPRAMIDE HCL		
AP		FAULDING	**EQ 5MG BASE/ML**	**N71990 001** JAN 18, 1989

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

		METOCLOPRAMIDE HCL		
		@ FAULDING	EQ 5MG BASE/ML	N71990 001 JAN 18, 1989

TABLET; ORAL

		METOCLOPRAMIDE HCL		
AB		MUTUAL PHARM	**EQ 5MG BASE**	**N71536 002** JAN 16, 1997

METOLAZONE

TABLET; ORAL

		MYKROX		
		MEDEVA	0.5MG	N19532 001 OCT 30, 1987
		+	0.5MG	N19532 001 OCT 30, 1987

METRONIDAZOLE

GEL; VAGINAL

		METROGEL-VAGINAL		
		+ 3M	0.75%	N20208 001 AUG 17, 1992
		+ CURATEK	0.75%	N20208 001 AUG 17, 1992

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

		MEXILETINE HCL		
AB		WATSON LABS	**150MG**	**N74711 001** FEB 26, 1997
AB			**200MG**	**N74711 002** FEB 26, 1997
AB			**250MG**	**N74711 003** FEB 26, 1997

MICONAZOLE NITRATE

LOTION; TOPICAL

		MONISTAT-DERM		
		@ J AND J	2%	N17739 001

MICONAZOLE NITRATE

LOTION; TOPICAL
MONISTAT-DERM
@ JOHNSON RW 2% N17739 001

MIRTAZAPINE

TABLET; ORAL
REMERON
+ ORGANON 30MG N20415 002 JUN 14, 1996
30MG N20415 002 JUN 14, 1996
+ 45MG N20415 003 MAR 17, 1997

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
PENTAZOCINE AND NALOXONE HYDROCHLORIDES
AB ROYCE LABS **EQ 0.5MG BASE; EQ 50MG BASE** **N74736 001** JAN 21, 1997

TALWIN NX
AB + SANOFI WINTHROP **EQ 0.5MG BASE; EQ 50MG BASE** **N18733 001** DEC 16, 1982

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION
TILADE
+ FISONS 1.75MG/INH N19660 001 DEC 30, 1992
+ RHONE POULENC RORER 1.75MG/INH N19660 001 DEC 30, 1992

NELFINAVIR MESYLATE

POWDER FOR RECONSTITUTION; ORAL
VIRACEPT
+ AGOURON EQ 50MG BASE/SCOOPFUL N20778 001 MAR 14, 1997

NELFINAVIR MESYLATE

TABLET; ORAL
VIRACEPT
+ AGOURON EQ 250MG BASE N20779 001 MAR 14, 1997

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING
NEO-RX
AA PHARMA TEK **100%** **N61579 001**
100% N61579 001

NEOMYCIN SULFATE
AA PADDOCK **100%** **N62385 001** JUN 01, 1982

ONDANSETRON HYDROCHLORIDE

SOLUTION; ORAL
ZOFRAN
+ GLAXO WELLCOME EQ 4MG BASE/5ML N20605 001 JAN 24, 1997

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
OXYBUTYNIN CHLORIDE
AA MORTON GROVE **5MG/5ML** **N74868 001** FEB 12, 1997

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN
+ PURDUE FREDERICK 10MG N20553 001 DEC 12, 1995
+ 20MG N20553 002 DEC 12, 1995
+ 40MG N20553 003 DEC 12, 1995
+ PURDUE PHARMA 10MG N20553 001 DEC 12, 1995
+ 20MG N20553 002 DEC 12, 1995

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN

+	PURDUE PHARMA	40MG	N20553 003	> DLT >	
			DEC 12, 1995	> ADD >	
+		80MG	N20553 004		
			JAN 06, 1997		

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
PHENDIMETRAZINE TARTRATE

> DLT >	BC	GRAHAM DM	105MG	N87214 001	> ADD >
> DLT >				MAY 26, 1982	> ADD >
> DLT >	BC		105MG	N88020 001	
> DLT >				AUG 16, 1982	
> DLT >	BC		105MG	N88028 001	
> DLT >				AUG 16, 1982	
> DLT >	BC		105MG	N88062 001	
> DLT >				SEP 13, 1982	
> DLT >	BC		105MG	N88063 001	
> DLT >				SEP 10, 1982	
> DLT >	BC		105MG	N88111 001	
> DLT >				OCT 18, 1982	
> ADD >	@		105MG	N87214 001	
> ADD >				MAY 26, 1982	
> ADD >	@		105MG	N88020 001	
> ADD >				AUG 16, 1982	
> ADD >	@		105MG	N88028 001	
> ADD >				AUG 16, 1982	
> ADD >	@		105MG	N88062 001	
> ADD >				SEP 13, 1982	
> ADD >	@		105MG	N88063 001	
> ADD >				SEP 10, 1982	
> ADD >	@		105MG	N88111 001	
> ADD >				OCT 18, 1982	

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL

AA	KING PHARMS	**30MG**	**N40083 001**	
			MAR 07, 1997	

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL
DILANTIN

	PARKE DAVIS	30MG	N84349 001	> DLT >	
				> ADD >	
+		30MG	N84349 001		

PINDOLOL

TABLET; ORAL
PINDOLOL

				> ADD >	
AB	LEMMON	**5MG**	**N74123 001**	> ADD >	
			APR 17, 1997		
AB		**10MG**	**N74123 002**	> ADD >	
			APR 17, 1997		

PODOFILOX

GEL; TOPICAL
CONDYLOX

+	OCLASSEN	0.5%	N20529 001	
			MAR 13, 1997	

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC
POLYTRIM

AT	+ ALLERGAN	**10,000 UNITS/ML;**		
		EQ 1MG BASE/ML	**N50567 001**	
			OCT 20, 1988	

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	BAUSCH AND LOMB	**10,000 UNITS/ML;**		
		EQ 1MG BASE/ML	**N64120 001**	
			FEB 14, 1997	

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL
PEDIAPRED

+	FISONS	EQ 5MG BASE/5ML	N19157 001
			MAY 28, 1986
+	MEDEVA	EQ 5MG BASE/5ML	N19157 001
			MAY 28, 1986

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

> DLT >	**AP**	STERIS	**EQ 5MG BASE/ML**	**N89605 001**	
> DLT >				**JUL 08, 1987**	
> ADD >		@	EQ 5MG BASE/ML	N89605 001	
> ADD >				JUL 08, 1987	

PROPANTHELINE BROMIDE

TABLET; ORAL
PROPANTHELINE BROMIDE

> DLT >	BP	PAR PHARM	15MG	N88377 001	
> DLT >				DEC 08, 1983	
> ADD >		@	15MG	N88377 001	
> ADD >				DEC 08, 1983	

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	ROXANE	**40MG**	**N70518 001**	
			JUL 07, 1986	
	@	40MG	N70518 001	
			JUL 07, 1986	

SAMARIUM SM 153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION
QUADRAMET

CYTOGEN	50mCi/ML	N20570 001	
		MAR 28, 1997	

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL
ELDEPRYL

AB	+ SOMERSET	**5MG**	**N20647 001**	
			MAY 15, 1996	
	+	5MG	N20647 001	
			MAY 15, 1996	

TABLET; ORAL
SELEGILINE HCL

> ADD >	**AB**	APOTHECON	**5MG**	**N74672 001**
> ADD >				APR 01, 1997

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
SELEGILINE HCL

AB	LEMMON	**5MG**	**N74744 001**	
			JAN 27, 1997	

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
NITROPRESS

AP	ABBOTT	**50MG/VIAL**	**N71555 001**	
			NOV 16, 1987	
	@	50MG/VIAL	N71555 001	
			NOV 16, 1987	

SULFAMETHOXAZOLE

SUSPENSION; ORAL
GANTANOL

+	ROCHE	500MG/5ML	N13664 002
	@	500MG/5ML	N13664 002

> ADD > TAMSULOSIN HYDROCHLORIDE

> ADD > CAPSULE; ORAL
> ADD > FLOMAX
> ADD > + BOEHRINGER INGELHEIM 0.4MG N20579 001
> ADD > APR 15, 1997

TERFENADINE

TABLET; ORAL
SELDANE

AB	+ HOECHST MARION RSSL	**60MG**	**N18949 001**	
			MAY 08, 1985	

TERFENADINE

AB	BAKER NORTON	**60MG**	**N74475 001**	
			JAN 03, 1997	

TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION
ACHROMYCIN

> DLT >	**AP**	+ LEDERLE	**250MG/VIAL**	**N50273 002**

TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ACHROMYCIN

> DLT >	AP		LEDERLE	500MG/VIAL	N50273 003
> ADD >		+		250MG/VIAL	N50273 002
> ADD >				500MG/VIAL	N50273 003
> DLT >			**TETRACYN**		
> DLT >	AP		PFIZER	250MG/VIAL	N60096 001
> DLT >	AP			500MG/VIAL	N60096 002
> ADD >		@		250MG/VIAL	N60096 001
> ADD >		@		500MG/VIAL	N60096 002

SUSPENSION; ORAL

TETRACYCLINE HCL

> DLT >	AB		ALPHARMA	125MG/5ML	N60633 001
> ADD >		@		125MG/5ML	N60633 001
> DLT >			**TETRACYN**		
> DLT >	AB		PFIPHARMECS	125MG/5ML	N60095 001
> ADD >		@		125MG/5ML	N60095 001

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

AP		DUPONT	1mCi/ML	N17806 001
AP	+		1mCi/ML	N17806 001
AP		MALLINCKRODT	1mCi/ML	N18150 001
AP	+		1mCi/ML	N18150 001
AP	+	MEDI PHYSICS	1mCi/ML	N18110 002
				FEB 27, 1996
			1mCi/ML	N18110 002
				FEB 27, 1996

THEOPHYLLINE

CAPSULE; ORAL

> DLT >			THEOPHYLLINE		
> DLT >	BP		KV PHARM	100MG	N85263 001
> DLT >	BP			200MG	N85263 002
> ADD >		@		100MG	N85263 001
> ADD >		@		200MG	N85263 002

CAPSULE, EXTENDED RELEASE; ORAL

> DLT >			SOMOPHYLLIN-CRT		
> DLT >	BC		GRAHAM DM	50MG	N87763 001
> DLT >					FEB 27, 1985

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

> DLT >			SOMOPHYLLIN-CRT		
> DLT >	BC		GRAHAM DM	100MG	N87194 001
> DLT >	BC			200MG	N88382 001
> DLT >					FEB 27, 1985
> DLT >	BC			250MG	N87193 001
> DLT >	BC			300MG	N88383 001
> DLT >					FEB 27, 1985
> ADD >		@		50MG	N87763 001
> ADD >					FEB 27, 1985
> ADD >		@		100MG	N87194 001
> ADD >		@		200MG	N88382 001
> ADD >					FEB 27, 1985
> ADD >		@		250MG	N87193 001
> ADD >		@		300MG	N88383 001
> ADD >					FEB 27, 1985

TILUDRONATE DISODIUM

TABLET; ORAL

		SKELID		
	+	SANOFI	EQ 200MG BASE	N20707 001
				MAR 07, 1997

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AT	ADV REMEDIES	EQ 0.25% BASE	N74465 001
			MAR 25, 1997
AT		EQ 0.5% BASE	N74466 001
			MAR 25, 1997
AT	AKORN	EQ 0.25% BASE	N74515 001
			MAR 25, 1997
AT		EQ 0.5% BASE	N74516 001
			MAR 25, 1997
AT	BAUSCH AND LOMB	EQ 0.25% BASE	N74778 001
			MAR 25, 1997
AT		EQ 0.5% BASE	N74776 001
			MAR 25, 1997
AT	FOUGERA	EQ 0.25% BASE	N74667 001
			MAR 25, 1997
AT		EQ 0.5% BASE	N74668 001
			MAR 25, 1997

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE

AT	PACIFIC PHARMA	**EQ 0.25% BASE**	**N74746 001**	MAR 25, 1997
AT		**EQ 0.5% BASE**	**N74747 001**	MAR 25, 1997

TIOCONAZOLE

OINTMENT; VAGINAL
VAGISTAT-1

+	BRISTOL MYERS	6.5%	N19355 001 DEC 30, 1986

TOLMETIN SODIUM

TABLET; ORAL
TOLMETIN SODIUM

> DLT > > DLT >	**AB**	BAKER NORTON	**EQ 600MG BASE**	**N74399 001**	MAR 28, 1996
	AB	LEMMON	**EQ 600MG BASE**	**N74729 001**	FEB 27, 1997
> ADD > > ADD >	**AB**	ZENITH GOLDLINE	**EQ 600MG BASE**	**N74399 001**	MAR 28, 1996

TOPIRAMATE

TABLET; ORAL
TOPAMAX

@	JOHNSON RW	400MG	N20505 006 DEC 24, 1996

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
TRAZODONE HCL

> ADD > > ADD >	**AB**	LEMMON	**150MG**	**N74357 001** APR 30, 1997

TRETINOIN

CREAM; TOPICAL
AVITA

AB	PENEDERM	**0.025%**	**N20404 003**	JAN 14, 1997

RETIN-A

AB	+ J AND J	**0.025%**	**N19049 001**	SEP 16, 1988

GEL; TOPICAL
RETIN-A MICRO

+	ADV POLYMER	0.1%	N20475 001 FEB 07, 1997

TRIAMCINOLONE ACETONIDE

LOTION; TOPICAL
TRIAMCINOLONE ACETONIDE

> DLT > > DLT >	**AT**	ALPHARMA	**0.1%**	**N87192 001**	SEP 08, 1982
> ADD > > ADD >		@	0.1%	N87192 001	SEP 08, 1982

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL
TRIHEXYPHENIDYL HCL

> ADD > > ADD > **AA**	PHARM ASSOC	**2MG/5ML**	**N40177 001**	APR 17, 1997

TROGLITAZONE

TABLET; ORAL
PRELAY

AB	SANKYO	**200MG**	**N20719 001**	JAN 29, 1997
AB		**400MG**	**N20719 002**	JAN 29, 1997

REZULIN

AB	PARKE DAVIS	**200MG**	**N20720 001**	JAN 29, 1997
AB		**400MG**	**N20720 002**	JAN 29, 1997

VINCRISTINE SULFATE

INJECTABLE; INJECTION

	VINCREX			
AP	+ BRISTOL MYERS	5MG/VIAL	N70867 001	
			JUL 12, 1988	
	@ BRISTOL MYERS SQUIBB	5MG/VIAL	N70867 001	
			JUL 12, 1988	
	VINCRISTINE SULFATE			
AP	FAULDING	5MG/VIAL	N71561 001	
			APR 11, 1988	
	+	5MG/VIAL	N71561 001	
			APR 11, 1988	

WARFARIN SODIUM

TABLET; ORAL

	COUMADIN			
AB	DUPONT MERCK	1MG	N09218 022	
			MAR 01, 1990	
AB	+	2MG	N09218 013	
AB		2.5MG	N09218 018	
AB		4MG	N09218 023	
			AUG 24, 1993	
AB		5MG	N09218 007	
AB		7.5MG	N09218 016	
AB	+	10MG	N09218 005	
	WARFARIN SODIUM			
AB	BARR	1MG	N40145 001	
			MAR 26, 1997	
AB		2MG	N40145 002	
			MAR 26, 1997	
AB		2.5MG	N40145 003	
			MAR 26, 1997	
AB		4MG	N40145 004	
			MAR 26, 1997	
AB		5MG	N40145 005	
			MAR 26, 1997	
AB		7.5MG	N40145 006	
			MAR 26, 1997	
AB		10MG	N40145 007	
			MAR 26, 1997	

ZINC ACETATE

CAPSULE; ORAL

	GALZIN			
	LEMMON	EQ 25MG ZINC	N20458 001	
			JAN 28, 1997	
	+	EQ 50MG ZINC	N20458 002	
			JAN 28, 1997	

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

COLD CAPSULE IV				
+ GRAHAM DM	12MG;75MG	N18793 001	> DLT >	
		APR 25, 1985	> DLT >	
@	12MG;75MG	N18793 001	> DLT >	
		APR 25, 1985		
COLD CAPSULE V				
GRAHAM DM	8MG;75MG	N18794 001		
		APR 23, 1985		
@	8MG;75MG	N18794 001		
		APR 23, 1985		

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE				
LEMMON	1.34MG	N73282 002	> ADD >	
		DEC 03, 1992	> ADD >	
TEVA	1.34MG	N73282 002		
		DEC 03, 1992		

CROMOLYN SODIUM

SPRAY, METERED; NASAL

NASALCROM				
+ MCNEIL	5.2MG/SPRAY	N20463 001		
		JAN 03, 1997		

IBUPROFEN

TABLET; ORAL

JUNIOR STRENGTH MOTRIN				
MCNEIL	100MG	N20602 001		
		JUN 10, 1996		
+	100MG	N20602 001		
		JUN 10, 1996		

INSULIN SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

> ADD > VELOSULIN BR HUMAN				
> ADD > + NOVO NORDISK	100 UNITS/ML	N19450 001		
> ADD >		MAY 30, 1986		

INSULIN SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

VELOSULIN HUMAN				
+ NOVO NORDISK	100 UNITS/ML	N19450 001		
		MAY 30, 1986		

MICONAZOLE NITRATE

CREAM; VAGINAL

MICONAZOLE NITRATE		
TARO	2%	N74444 001
		JAN 13, 1997

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE		
> ADD > G AND W LABS	100MG	N74414 001
> ADD >		APR 30, 1997
+ PERRIGO	100MG	N74395 001
		MAR 20, 1997

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL (FOR MEN)		
MORTON GROVE	2%	N74767 001
		FEB 28, 1997

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM		
INVAMED	EQ 200MG BASE	N74646 001
		JAN 13, 1997
NOVOPHARM	EQ 200MG BASE	N74635 001
		JAN 13, 1997
PERRIGO	EQ 200MG BASE	N74661 001
		JAN 13, 1997
PVT FORM	EQ 200MG BASE	N74789 001
		FEB 27, 1997

TIOCONAZOLE

OINTMENT; VAGINAL
VAGISTAT-1
+ BRISTOL MYERS SQUIBB 6.5% N20676 001
FEB 11, 1997

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 4/ APR '97

NO APRIL APPROVALS

Orphan Product Designations and Approvals List
January 1997 through April 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
8 Cyclopentyl 1,3-dipropylxanthine TN=	Treatment of cystic fibrosis.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Boulevard Suite 315 San Mateo, CA 94404 DD=03/24/1997
9-cis-retinoic acid TN=	Prevention of retinal detachment due to proliferative vitreoretinopathy.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine, CA 92623 DD=01/02/1997
Anagrelide TN= Agrylin	Treatment of essential thrombocythemia.	Roberts Pharmaceutical Corp. Meridian Center III 6 Industrial Way West Eatontown, NJ 07724 DD=01/27/1988 MA=03/14/1997
Beta alethine TN= Betathine	Treatment of multiple myeloma.	Dovetail Technologies, Inc. 10615 Mantz Road Silver Spring, MD 20903 DD=03/24/1997
Beta alethine TN= Betathine	Treatment of metastatic melanoma.	Dovetail Technologies, Inc. 10615 Mantz Road Silver Spring, MD 20903 DD=03/24/1997
Coagulation Factor IX (recombinant) TN= BeneFix	Treatment of hemophilia B.	Genetics Institute, Inc. 87 Cambridge Park Drive Cambridge, MA 02140 DD=10/03/1994 MA=02/11/1997

Orphan Product Designations and Approvals List
January 1997 through April 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Dehydroepiandrosterone sulfate sodium TN=	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City, UT 84109 DD=01/28/1997
Dehydroepiandrosterone sulfate sodium TN=	Treatment of serious burns requiring hospitalization.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City, UT 84109 DD=01/29/1997
Dimethylsulfoxide TN=	Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson, AZ 85710 DD=04/15/1997
Enadoline hydrochloride TN=	Treatment of severe head injury.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor, MI 48105 DD=01/28/1997
Gp100 adenoviral gene therapy TN=	Treatment of metastatic melanoma.	Genzyme Corporation P.O. Box 9322 One Mountain Road Framingham, MA 01701 DD=03/25/1997
Lepirudin TN= Refludan	Treatment of heparin-associated thrombocytopenia Type II.	Behringwerke AG P.O. Box 1140 D-35001 Marburg Germany, DD=02/13/1997

Orphan Product Designations and Approvals List
January 1997 through April 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Levocarnitine TN= Carnitor	Treatment of zidovudine-induced mitochondrial myopathy.	Sigma-Tau Pharmaceuticals, Inc. 800 S. Frederick Avenue, Suite 300 Gaithersburg, MD 20877 DD=04/07/1997
MART-1 adenoviral gene therapy for malignant melanoma TN=	Treatment of metastatic melanoma.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=03/28/1997
Oxandrolone TN= Oxandrin	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Bio-Technology General Corporation 70 Wood Avenue South Iselin, NJ 08830 DD=04/22/1997
Paclitaxel TN= Taxol	Treatment of AIDS-related Kaposi's sarcoma.	Bristol-Myers Squibb Pharmaceutical Research Institute 5 Research Parkway P.O. Box 5100 Wallingford, CT 06492 DD=03/25/1997
Paclitaxel TN= Paxene	Treatment of AIDS-related Kaposi's sarcoma.	Baker Norton Pharmaceuticals, Inc. 4400 Biscayne Boulevard Miami, FL 33137 DD=04/15/1997
Patul-end TN=	Treatment of patulous eustachian tube.	Ear Foundation 24209 Castillo Street, Suite 100 Santa Barbara, CA 93105 DD=02/18/1997

Orphan Product Designations and Approvals List
January 1997 through April 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Poly-ICLC TN=	Treatment of primary brain tumors.	Salazar, Andres M. M.D. and Levy, Hilton B. Ph.D. 3202 Cleveland Avenue N.W. Washington, DC 20008 DD=03/17/1997
Porfiromycin TN= Promycin	Treatment of cervical cancer.	Vion Pharmaceuticals, Inc. Four Science Park New Haven, CT 06511 DD=03/13/1997
Zinc acetate TN= Galzin	Treatment of Wilson's disease.	Lemmon Company 1510 Delp Drive Kulpsville, PA 19443 DD=11/06/1985 MA=01/28/1997

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO APRIL 1997 ADDITIONS

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 17TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS

NEW INDICATION

I-177	TREATMENT OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15 YEARS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
I-178	TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
I-179	NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
I-180	TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
I-181	TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
I-182	TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
I-183	MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
I-184	TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2 MG/DAY (MAXIMUM OF 4MG)
I-185	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

PATENT USE CODE

U-161	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
U-162	METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
U-163	METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
U-164	METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
U-165	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
U-166	TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER
U-167	METHOD FOR TREATING HIV-1 INFECTION
U-168	METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA
U-169	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
U-170	METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT

EXCLUSIVITY TERMS

PATENT USE CODE

U-171	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
U-172	TREATMENT OF GENITAL WARTS
U-173	ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
U-174	USE AS AN ANTIHISTAMINE AGENT
U-175	METHOD OF TREATING MALIGNANT TUMORS
U-176	METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSIS
U-177	FUNGICIDE
U-178	FACILITATED ADHERENCE OF AGENTS TO SKIN
U-179	ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
U-180	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-181	PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
U-182	USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020059	001	ADENOSINE;ADENOSCAN	5070877	MAY 18, 2009	U-116		
>DLT>	020059	001	ADENOSINE;ADENOSCAN	5070877	DEC 10, 2008	U-116		
	020291	001	ALBUTEROL SULFATE;COMBIVENT	5603918	JUN 09, 2015		NC	OCT 24, 1999
	020503	001	ALBUTEROL SULFATE;PROVENTIL-HFA	5225183	JUL 06, 2010		NP	AUG 15, 1999
				5439670	JUL 06, 2010			
				5605674	FEB 25, 2014			
>ADD>	020560	001	ALENDRONATE SODIUM;FOSAMAX				I-185	APR 25, 2000
>ADD>	020560	002	ALENDRONATE SODIUM;FOSAMAX				I-185	APR 25, 2000
>ADD>	020560	003	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012		NS	APR 25, 2000
>ADD>				4621077	NOV 04, 2003	U-114	I-185	APR 25, 2000
	020333	001	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
							NCE	MAR 14, 2002
	020333	002	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
							NCE	MAR 14, 2002
	020702	001	ATORVASTATIN CALCIUM;LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
				5273995	DEC 28, 2010	U-162		
				5385929	MAY 04, 2014	U-59		
	020702	002	ATORVASTATIN CALCIUM;LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
				5273995	DEC 28, 2010	U-162		
				5385929	MAY 04, 2014	U-59		
	020702	003	ATORVASTATIN CALCIUM;LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
				5273995	DEC 28, 2010	U-162		
				5385929	MAY 04, 2014	U-59		
	020486	001	BECLOMETHASONE DIPROPIONATE;VANCERIL DOUBLE STRENGTH				NP	DEC 24, 1999
>ADD>	020032	001	BERACTANT;SURVANTA	4397839	JUL 01, 2005			
>DLT>	020032	001	BERACTANT;SURVANTA	4397839	AUG 10, 2000			
>ADD>	020619	001	BETAXOLOL HYDROCHLORIDE;BETOPTIC PILO				NC	APR 17, 2000
	020490	001	BRIMONIDINE TARTRATE;ALPHAGAN				NP	MAR 13, 2000
							NCE	SEP 06, 2001
	018644	002	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5358970	AUG 12, 2013			
	018644	003	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5358970	AUG 12, 2013			
>ADD>	020524	001	BUTENAFINE HYDROCHLORIDE;MENTAX	5021458	JUN 04, 2008	U-177		
	019881	001	BUTOCONAZOLE NITRATE;FEMSTAT ONE	4078071	MAR 07, 1997		NP	FEB 07, 2000
	020664	001	CABERGOLINE;DOSTINEX	4526892	JUL 02, 2002		NCE	DEC 23, 2001
	020273	001	CALCIPOTRIENE;DOVONEX	4866048	SEP 12, 2006		D-33	MAR 20, 2000
	020554	001	CALCIPOTRIENE;DOVONEX				NCE	DEC 29, 1998
	020611	001	CALCIPOTRIENE;DOVONEX	4866048	SEP 12, 2006		NDF	MAR 03, 2000
							NCE	DEC 29, 1998
>ADD>	019880	001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
>DLT>	019880	001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-32		
>ADD>	019880	002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
>DLT>	019880	002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-32		
>ADD>	019880	003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
>DLT>	019880	003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-32		
>ADD>	019835	001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
>DLT>	019835	001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2002			
>ADD>	019835	002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
>DLT>	019835	002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2002			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020346	001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
>DLT>	020346	001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2002			
	019847	001	CIPROFLOXACIN;CIPRO	4705789	NOV 10, 2004		I-179	OCT 21, 1999
	019857	001	CIPROFLOXACIN;CIPRO IN DEXTROSE 5%	4808583	FEB 28, 2006		I-179	OCT 21, 1999
	019858	001	CIPROFLOXACIN;CIPRO IN SODIUM CHLORIDE 0.9%	4705789	NOV 10, 2004		I-179	OCT 21, 1999
>ADD>	017533	001	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
>ADD>	017533	002	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
>ADD>	017533	003	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
>ADD>	017533	005	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
>ADD>	017533	006	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	020463	001	CROMOLYN SODIUM;NASALCROM				NP	JAN 03, 2000
	020430	001	DANAPAROID SODIUM;ORGARAN	5164377	OCT 03, 2010			
>ADD>	020705	001	DELAVIRDINE MESYLATE;RESCRIPTOR	5563142	OCT 08, 2013		NCE	APR 04, 2002
	020037	001	DICLOFENAC SODIUM;VOLTAREN	4960799	OCT 03, 2007			
				4829088	APR 14, 2007			
>ADD>	020154	002	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
>ADD>	020154	003	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
>ADD>	020154	004	DIDANOSINE;VIDEX	5616566	AUG 29, 2000	U-180		
>ADD>	020154	005	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
>ADD>	020155	003	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
>ADD>	020155	004	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
>ADD>	020155	005	DIDANOSINE;VIDEX	5616566	AUG 29, 2000	U-180		
>ADD>	020156	001	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	018723	001	DIVALPROEX SODIUM;DEPAKOTE				I-181	JUN 20, 1999
	018723	002	DIVALPROEX SODIUM;DEPAKOTE				I-181	JUN 20, 1999
	018723	003	DIVALPROEX SODIUM;DEPAKOTE				I-181	JUN 20, 1999
	019680	001	DIVALPROEX SODIUM;DEPAKOTE	4988731	JAN 29, 2008		I-181	JUN 20, 1999
>ADD>	020668	001	ENALAPRIL MALEATE;LEXXEL	4472380	SEP 18, 2001			
>ADD>				4374829	DEC 30, 2001	U-3		
>ADD>				4703038	OCT 07, 2005	U-3		
	020417	001	ESTRADIOL;FEMPATCH	4906463	MAR 06, 2007		NP	DEC 03, 1999
				5006342	APR 09, 2008			
	019697	001	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66	I-177	DEC 31, 1999
	019697	002	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66	I-177	DEC 31, 1999
	018922	005	ETODOLAC;LODINE				I-24	JUN 28, 1999
	020410	001	FERUMOXSIL;GASTROMARK	5219554	JUN 15, 2010		NCE	DEC 06, 2001
				5069216	MAY 09, 2006	U-171		
				5055288	OCT 08, 2008			
				4951675	SEP 13, 2005	U-169		
				4827945	MAY 09, 2006	U-170		
				4770183	SEP 13, 2005	U-169		
				4695393	SEP 22, 2004			
				4695392	SEP 22, 2004			
	020235	001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000			
	020235	002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000			
	020235	003	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000			
	020622	001	GLATIRAMER ACETATE;COPAXONE				ODE	DEC 20, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020329	001	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
	020329	002	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
	020267	002	IBUPROFEN;JUNIOR STRENGTH ADVIL				NP	JUN 16, 1998
	020723	001	IMIQUIMOD;ALDARA	4689338	AUG 25, 2004	U-172	NCE	FEB 27, 2002
				5238944	AUG 24, 2010			
>ADD>	040024	001	IRON DEXTRAN;DEXFERRUM	5624668	SEP 29, 2015			
	020083	001	ITRACONAZOLE;SPORANOX				I-178	DEC 06, 1999
	020657	001	ITRACONAZOLE;SPORANOX				NDF	FEB 21, 2000
>ADD>	020708	001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	4652411	NOV 01, 2004			
>ADD>				4677191	JUL 03, 2005			
>ADD>				4728721	MAY 01, 2006			
>ADD>				4849228	JUL 18, 2006			
>ADD>				4917893	NOV 01, 2004			
>ADD>				4954298	NOV 01, 2004			
>ADD>				5330767	NOV 01, 2004			
>ADD>				5476663	APR 17, 2007			
>ADD>				5480656	JAN 02, 2013			
>ADD>				5575987	NOV 19, 2013			
	020641	001	LORATADINE;CLARITIN	4659716	APR 21, 2004	U-142		
	020704	001	LORATADINE;CLARITIN REDITABS	4282233	JUN 19, 2002	U-77	NCE	APR 12, 1998
				4659716	APR 21, 2004	U-142		
>ADD>	020357	001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
>DLT>	020357	001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	DEC 29, 1999
>ADD>	020357	002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
>DLT>	020357	002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	DEC 29, 1999
	019660	001	NEDOCROMIL SODIUM;TILADE				I-183	MAR 06, 2000
	020778	001	NELFINAVIR MESYLATE;VIRACEPT				NCE	MAR 14, 2002
	020779	001	NELFINAVIR MESYLATE;VIRACEPT				NCE	MAR 14, 2002
	020636	001	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011	U-167	NCE	JUN 21, 2001
>ADD>	020592	001	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
>ADD>	020592	002	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
>ADD>	020592	003	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
>ADD>	020592	004	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
	020688	001	OLOPATADINE HYDROCHLORIDE;PATANOL	4871865	OCT 03, 2006			
				4923892	MAY 08, 2007	U-174		
				5116863	MAY 26, 2009			
	019810	001	OMEPRAZOLE;PRILOSEC	4636499	MAY 30, 2005			
				5093342	FEB 02, 2010	U-166		
				5599794	FEB 04, 2014	U-166		
	019810	003	OMEPRAZOLE;PRILOSEC	4636499	MAY 30, 2005			
				5093342	FEB 02, 2010	U-166		
				5599794	FEB 04, 2014	U-166		
	020605	001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	JUN 24, 2006	U-44		
>ADD>	020031	001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-150	MAY 07, 1999
>DLT>	020031	001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	SEP 24, 2008			
>ADD>	020031	002	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-150	MAY 07, 1999
>DLT>	020031	002	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	SEP 24, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020031	004	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-150	MAY 07, 1999
>DLT>	020031	004	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	SEP 24, 2008			
>ADD>	020031	005	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-150	MAY 07, 1999
>DLT>	020031	005	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	SEP 24, 2008			
>ADD>	018796	001	PILOCARPINE HYDROCHLORIDE;PILOPINE HS	4271143	MAY 09, 1999			
>DLT>	018796	001	PILOCARPINE HYDROCHLORIDE;PILOPINE HS	4271143	JUN 02, 1998			
>ADD>	020529	001	PODOFILOX;CONDYLOX	4680399	JUL 14, 2004		NDF	MAR 13, 2000
>ADD>				5057616	OCT 15, 2008			
	019627	002	PROPOFOL;DIPRIVAN				NP	JUN 11, 1999
>ADD>	020272	001	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
>ADD>	020272	002	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
>ADD>	020272	003	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
>ADD>	020272	004	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
>ADD>	020588	001	RISPERIDONE;RISPERDAL	5453425	JUN 11, 2014			
>ADD>				5616587	JUN 11, 2014			
>ADD>	020236	001	SALMETEROL XINAFOATE;SEREVENT	5380922	JAN 10, 2012			
>DLT>	020236	001	SALMETEROL XINAFOATE;SEREVENT	5380922	MAY 14, 2013			
>ADD>				5225445	FEB 12, 2008	U-182		
	020570	001	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM;QUADRAMET				NCE	MAR 28, 2002
	020570	002	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM;QUADRAMET				NCE	MAR 28, 2002
	019640	001	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				ODE	DEC 30, 2003
	019640	004	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				ODE	DEC 30, 2003
	020168	001	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	DEC 30, 2003
							I-182	DEC 30, 1999
	020168	002	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	DEC 30, 2003
							I-182	DEC 30, 1999
>ADD>	020579	001	TAMSULOSIN HYDROCHLORIDE;FLOMAX	4868216	SEP 19, 2006	U-181	NCE	APR 15, 2002
>ADD>				4731478	OCT 27, 2004			
>ADD>				4703063	OCT 27, 2004			
>ADD>				4772475	FEB 27, 2006			
	019057	001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
						U-3		
	019057	002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
						U-3		
	019057	003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
						U-3		
	019057	004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
						U-3		
	020347	001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-3		
						U-165		
	020347	002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165		
						U-3		
	020347	003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165		
						U-3		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020347	004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165		
						U-3		
	020192	001	TERBINAFINE HYDROCHLORIDE;LAMISIL				I-180	JAN 21, 2000
	020707	001	TILUDRONATE DISODIUM;SKELID	4876248	OCT 24, 2006		NCE	MAR 07, 2002
				4980171	APR 06, 2009			
	020676	001	TIOCONAZOLE;VAGISTAT-1				NP	FEB 11, 2000
>ADD>	020404	003	TRETINOIN;AVITA	4971800	NOV 20, 2007	U-178		
>ADD>				5045317	SEP 03, 2008	U-179		
>ADD>	020475	001	TRETINOIN;RETIN-A MICRO	4690825	OCT 04, 2005	U-134	NP	FEB 07, 2000
>ADD>	020326	001	TRIMETREXATE GLUCURONATE;NEUTREXIN	4376858	MAY 09, 2004			
>DLT>	020326	001	TRIMETREXATE GLUCURONATE;NEUTREXIN	4376858	OCT 31, 2000			
	020719	001	TROGLITAZONE;PRELAY	5478852	SEP 15, 2013	U-163	NCE	JAN 29, 2002
				5457109	SEP 15, 2013	U-164		
				4572912	AUG 28, 2004			
				5104888	AUG 28, 2004			
				5602133	SEP 15, 2013	U-173		
	020719	002	TROGLITAZONE;PRELAY	5478852	SEP 15, 2013	U-163	NCE	JAN 29, 2002
				5457109	SEP 15, 2013	U-164		
				4572912	AUG 28, 2004			
				5104888	AUG 28, 2004			
				5602133	SEP 15, 2013	U-173		
	020720	001	TROGLITAZONE;REZULIN	5478852	SEP 15, 2013	U-163	NCE	JAN 29, 2002
				5457109	SEP 15, 2013	U-164		
				4572912	AUG 28, 2004			
				5104888	AUG 28, 2004			
				5602133	SEP 15, 2013	U-173		
	020720	002	TROGLITAZONE;REZULIN	5478852	SEP 15, 2013	U-163	NCE	JAN 29, 2002
				5457109	SEP 15, 2013	U-164		
				4572912	AUG 28, 2004			
				5104888	AUG 28, 2004			
				5602133	SEP 15, 2013	U-173		
	020665	001	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3		
	020665	002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3		
	020471	001	ZILEUTON;ZYFLO	4873259	FEB 10, 2007	U-168		
	020471	003	ZILEUTON;ZYFLO	4873259	FEB 10, 2007	U-168		
	020458	001	ZINC ACETATE;GALZIN				NP	JAN 28, 2000
							ODE	JAN 28, 2004
	020458	002	ZINC ACETATE;GALZIN				NP	JAN 28, 2000
							ODE	JAN 28, 2004

*U.S. Government Printing Office: 1997 - 417-599/40011

New 17th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7971

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** enter my subscription as follows:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $77.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐☐☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Credit card expiration date)

Thank you for your order!

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(_____)_____
Daytime phone including area code

_____
Purchase Order No. (optional)

_____
(Authorizing Signature)

(10/96)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.